Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
Active, not recruiting · NCT04034810
Conditions: Intracranial Aneurysm, Flow Diverter
At a glance
- Research payments reported, 2025
- $19,325
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 234
About the trial
- Sponsor
- Balt Extrusion
- Tested
- Intracranial aneurysm treated with Silk vista and silk vista baby (device)
- Dates
- Started 2019-11-04; completion 2027-11-30
- Results posted
- Not yet
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms. All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study. The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Balt USA, LLC reported $19,325 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $19,325
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.